Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy:A case series and analysis of the National Cancer Database
- Author:
McKenzie L. SCHAEFER
1
;
Patrick L. QUINN
;
Alexander H. SHANNON
;
Laith ABUSHAHIN
;
Jordan M. CLOYD
;
Mary E. DILLHOFF
;
Ning JIN
;
Ashish MANNE
;
Arjun MITTRA
;
Anne M. NOONAN
;
Timothy M. PAWLIK
;
Shafia RAHMAN
;
Aslam EJAZ
Author Information
- Publication Type:Original Article
- From: Annals of Hepato-Biliary-Pancreatic Surgery 2026;30(1):58-66
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:s/Aims: The role of surgery for pancreatic ductal adenocarcinoma (PDAC) with synchronous liver metastases remains controversial. Previous studies assessing the outcomes of combined surgery for primary PDAC and liver metastases have been limited by the inconsistent application of neoadjuvant chemotherapy (NAC).
Methods:We identified patients with PDAC and fewer than three liver metastases who received at least six months of NAC and underwent simultaneous pancreas and liver resection between January 2018 and March 2023 at a single institution. Additionally, we queried the National Cancer Database (NCDB) from 2010 to 2019 to identify patients with synchronous metastatic PDAC to the liver who received NAC before simultaneous resection, serving as a comparison group.
Results:Ten patients met the inclusion criteria for the institutional case series, with seven ultimately undergoing simultaneous resection. Among 224 patients in the NCDB who underwent simultaneous pancreas and liver resection, 70 patients (31.2%) received NAC.After a median follow-up of 59 months in the institutional cohort, five patients experienced recurrence, resulting in a median disease-free survival of four months (95% confidence interval [CI] 3, not reached). After controlling for confounding factors in the NCDB cohort, the administration of NAC was associated with improved survival (hazard ratio: 0.44, 95% CI 0.29–0.65, p < 0.001) compared to those who underwent upfront surgery.
Conclusions:Neoadjuvant therapy followed by simultaneous liver and pancreas resection for metastatic PDAC is safe and feasible, and it may provide a survival benefit in carefully selected patient populations.
